종양학 동반진단 시장 규모, 점유율, 동향 분석 리포트 : 제품 및 서비스별, 기술별, 제품 유형별, 질환 유형별, 최종 용도별, 지역별, 부문 예측(2024-2030년)

Oncology Companion Diagnostic Market Size, Share & Trends Analysis Report By Product & Service, By Technology (IHC, NGS), By Disease Type (Breast Cancer, Leukemia), By End Use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,152,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,522,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,262,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

종양학 동반진단 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 종양학 동반진단 시장 규모는 2024-2030년 8.7%의 CAGR로 확대하며, 2030년까지 83억 8,000만 달러에 달할 것으로 예측됩니다.

동반자 진단을 통해 중요한 유전체 정보에 대한 접근성을 확대함으로써 정보에 입각한 의사결정을 내리고 환자를 위한 표적 치료 접근법을 설계할 수 있으므로 종합적인 게놈 검사 및 종양학 동반진단에 대한 수요가 증가하고 있습니다.

그리벡(글리벡), 허셉틴(트라스투주맙) 등 처방 전 동반진단(CDx) 검사를 필요로 하는 약물의 출시로 인해 종양학 동반진단 매출은 증가하고 있습니다. 이러한 성장은 앞으로도 계속될 것으로 예상되는데, 임상시험 중인 상당수의 CDx 관련 암 치료제가 임상시험에서 CDx가 치료의 독점적 또는 종합적인 검사로 기능하는 것 외에도 임상시험에서 참가자 선발에 중요한 역할을 하고 있기 때문입니다. 환자가 바이오마커 표적을 가지고 있다면 신약 후보물질이 더 높은 반응률을 보일 가능성이 높기 때문입니다.

CDx 사용에 따른 경제적 인센티브는 의약품 개발자들이 의약품과 진단 테스트를 결합하도록 장려하고 있습니다. 그러나 진단약 제조업체들은 한편으로는 지불자/의료 서비스 프로바이더, 다른 한편으로는 의약품 제조업체의 상반된 요구에 직면해 있습니다. 또한 규제 당국은 진단과 의약품의 개발 일정을 일치시키기 위해 엄격한 정책을 시행하고 있습니다. 이에 따라 진단약 제조업체는 단일 진단약과 특정 약품의 매칭에 초점을 맞추기보다는 CDx 개발의 범위를 넓혀야할 것으로 예상됩니다.

종양학 동반진단 시장 보고서 하이라이트

• 2023년 시장 점유율은 운동기 보철 장비가 42.8.0% 이상을 차지할 것으로 예상되며, 그 뒤를 이어 시각 인공와우가 그 뒤를 이을 것입니다. 한편, 망막 신경 보철은 보급률 증가와 제품 혁신에 대한 연구개발 노력 증가로 인해 가장 빠르게 성장하는 시장 부문 중 하나로 확인되었습니다.
• 척수자극요법(SCS) 분야는 허혈성 통증, 요추 수술 실패 증후군, 난치성 통증 증후군 치료에 사용되는 SCS 치료의 진통 특성으로 인해 49.2% 이상의 가장 큰 점유율을 차지했습니다. 또한 척추내 및 경막외 미세자극을 통한 다리 운동 유발에도 적용되고 있습니다. 또한 이 분야의 기술 발전은 가까운 미래에 시장 성장을 더욱 촉진할 것으로 예상됩니다. 천골신경자극(SNS)은 만성 난치성 골반통과 신경인성 방광에 적용되어 예측 기간 중 가장 빠른 성장이 예상되는 분야입니다.
• 용도에서는 파킨슨병과 간질 증가로 인해 운동 신경 장애가 가장 큰 부분을 차지하고 있습니다. 예를 들어 파킨슨병 재단(Parkinson's disease Foundation)이 2012년에 발표한 보고서에 따르면 매년 약 6만 명의 미국인이 파킨슨병 진단을 받고 있으며, 이 수치는 예측 기간 중 더 늘어날 것으로 예상되어 이 부문의 성장에 박차를 가할 것으로 보입니다.
• 2023년 북미는 전체 신경 인공장기 시장의 42.5% 이상을 차지했습니다. 이는 많은 신경 임플란트 제조업체의 존재, 높은 연구개발 투자, 정부와 민간 기관으로부터의 자금 지원으로 인한 것으로 분석됩니다. 예를 들어 국방고등연구계획국(DARPA)과 국립신경장애 및 뇌졸중 연구소(NIH)는 연방 기관과 협력하여 신경 임플란트의 추가 개발을 위한 연구개발 구상을 지원하기 위해 자금을 지원하고 있습니다.
• 아시아태평양은 안전하고 효과적인 의료 절차를 촉진하는 다국적 헬스케어의 도입과 소비자의 인식 수준 향상으로 인해 가장 빠르게 성장하는 분야로 예상되고 있습니다.
• 전략적 제휴와 M&A는 예측 기간 중 업계의 경쟁 수준을 높게 유지할 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 종양학 동반진단 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 종양학 동반진단 시장 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTEL 분석

제4장 종양학 동반진단 시장 : 제품과 서비스 추정·동향 분석

• 세계의 종양학 동반진단 시장 : 제품과 서비스 대시보드
• 세계의 종양학 동반진단 시장 : 제품과 서비스의 변동 분석
• 세계의 종양학 동반진단 시장 : 제품·서비스별 매출
• 제품
• 서비스

제5장 종양학 동반진단 시장 : 기술 추정·동향 분석

• 세계의 종양학 동반진단 시장 : 기술 대시보드
• 세계의 종양학 동반진단 시장 : 기술 변동 분석
• 세계의 종양학 동반진단 시장 : 기술별 매출
• 중합효소 연쇄 반응(PCR)
• 차세대 시퀀싱(NGS)
• 면역조직화학(IHC)
• In Situ Hybridization(ISH)/Fluorescence In Situ Hybridization(FISH)
• 기타 테크놀러지

제6장 종양학 동반진단 시장 : 질환 유형 추정·동향 분석

• 세계의 종양학 동반진단 시장 : 질환 유형 대시보드
• 세계의 종양학 동반진단 시장 : 질환 유형의 변동 분석
• 세계의 종양학 동반진단 시장 : 질환 유형별 매출
• 유방암
• 비소세포 폐암
• 대장암
• 백혈병
• 악성 흑색종
• 전립선암
• 기타

제7장 종양학 동반진단 시장 : 최종 용도의 추정·동향 분석

• 세계의 종양학 동반진단 시장 : 최종 용도 대시보드
• 세계의 종양학 동반진단 시장 : 최종 용도 변동 분석
• 세계의 종양학 동반진단 시장 : 최종 용도별 매출
• 병원
• 병리학/진단 연구실
• 아카데믹 의료 센터

제8장 종양학 동반진단 시장 : 지역별 추정·동향 분석

• 지역 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제9장 경쟁 구도

• 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 구도
  • 주요 판매 대리점 및 채널 파트너 리스트
  • 주요 고객
  • 주요 기업의 시장 점유율 분석, 2023년
  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Foundation Medicine, Inc.
  • Myriad Genetics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • BioMerieux
  • Abbott
  • Leica Biosystems
  • Guardant Health, Inc.
  • EntroGen, Inc.

KSA

영문 목차

영문목차

Oncology Companion Diagnostic Market Growth & Trends:

The global oncology companion diagnostic market size is expected to reach USD 8.38 billion by 2030, expanding at a CAGR of 8.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Expanding access to important genomic information with the aid of companion diagnostics enables informed decision making for designing the targeted treatment approaches for their patients, thereby increasing demand for comprehensive genomic testing and oncology companion diagnostics.

The commercial launch of drugs including Gleevec (imatinib) and Herceptin (trastuzumab) that require Companion Diagnostics (CDx) testing before prescription has increased revenue generation in the oncology companion diagnostics field. This growth is expected to continue in the future owing to a substantial number of CDx associated oncology drugs in clinical trials. Apart from functioning as exclusive or inclusive tests for therapies, CDx also plays a crucial role during participant selection in clinical trials. This is because there is an increased potential for a novel drug candidate to show a better response rate if the patient has its biomarker target.

The economic incentives associated with the use of CDx have encouraged drug developers to combine their drugs with diagnostic tests. However, the diagnostic manufacturers face conflicting demands from payers/providers on one hand and drug manufacturers on the other hand. The regulatory bodies also have stringent policies to align the development timelines of diagnostics and drugs. Therefore, the diagnostic companies are expected to broaden their scope of CDx development instead of focusing on the attainment of a match between a single diagnostic with a specific drug.

Oncology Companion Diagnostic Market Report Highlights:

• The motor prosthetic devices segment dominated in terms of revenue share and accounted for over 42.8.0% of the market in 2023, followed by visual cochlear implants. Whereas, retinal neuroprosthetics were identified as one of the fastest growing market segment owing to the rising penetration and the increasing R&D efforts pertaining to product innovation.
• The Spinal Cord Stimulation (SCS) segment held the largest share at over 49.2% owing to the analgesic property of the SCS therapy used in the treatment of ischemic pain, failed back surgery syndrome, and complex refractory pain syndrome. Furthermore, it finds applications in intraspinal and epidural microstimulation for inducing leg movements. In addition, technological advancements in this segment is expected to further boost market growth in the near future. The sacral Nerve Stimulation (SNS) is expected to be the fastest growing segment over the forecast period due to its applications in chronic intractable pelvic ache and neurogenic bladder.
• In the applications segment, motor neuron disorders held the largest segment due to the rising incidences of Parkinson's disease and epilepsy. For instance, as per the report published by Parkinson's disease Foundation in 2012, approximately 60,000 Americans were diagnosed with Parkinson's disease each year and the number is expected to grow further over the forecast period thereby fueling this segment's growth.
• In 2023, North America dominated the overall neuroprosthetics market at over 42.5% owing to the large presence of neural implants manufacturers, higher R&D investments, and the availability of funds from both government and private institutes. For instance, the Defense Advanced Research Project Agency (DARPA) and National Institute of Neurological Disorders and Stroke (NIH)in collaboration with the federal agencies are instrumental in providing funds to support R&D initiatives for the further development of neural implants.
• Asia Pacific is anticipated to be the fastest growing segment due to the introduction of multinational healthcare establishments promoting safe and effective medical procedures along with the rising awareness levels amongst consumers.
• Strategic collaborations and mergers & acquisitions are expected to keep the industry rivalry level high over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product & Services
  • 1.2.2. Technology
  • 1.2.3. Disease Type
  • 1.2.4. End-use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product & services and technology outlook
  • 2.2.2. Disease type and end-use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Oncology Companion Diagnostic Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cancer
    • 3.2.1.2. Growing adoption of companion diagnostics
    • 3.2.1.3. Rising emphasis on personalized medicine
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Complex regulatory landscape
    • 3.2.2.2. Limited awareness and adoption in developing countries
• 3.3. Oncology Companion Diagnostic Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Oncology Companion Diagnostic Market: Product & Services Estimates & Trend Analysis

• 4.1. Global Oncology Companion Diagnostic Market: Product & Services Dashboard
• 4.2. Global Oncology Companion Diagnostic Market: Product& Services Movement Analysis
• 4.3. Global Oncology Companion Diagnostic Market by Product& Services, Revenue
• 4.4. Product
  • 4.4.1. Product market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Instruments
    • 4.4.2.1. Product market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Consumables
    • 4.4.3.1. Consumables market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Software
    • 4.4.4.1. Software market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Services
  • 4.5.1. Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Oncology Companion Diagnostic Market: Technology Estimates & Trend Analysis

• 5.1. Global Oncology Companion Diagnostic Market: Technology Dashboard
• 5.2. Global Oncology Companion Diagnostic Market: Technology Movement Analysis
• 5.3. Global Oncology Companion Diagnostic Market by Technology, Revenue
• 5.4. Polymerase Chain Reaction (PCR)
  • 5.4.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Next-generation Sequencing (NGS)
  • 5.5.1. Next-generation Sequencing (NGS) market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Immunohistochemistry (IHC)
  • 5.6.1. Immunohistochemistry (IHC) market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
  • 5.7.1. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH) market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Other Technologies
  • 5.8.1. Other technologies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Oncology Companion Diagnostic Market: Disease Type Estimates & Trend Analysis

• 6.1. Global Oncology Companion Diagnostic Market: Disease Type Dashboard
• 6.2. Global Oncology Companion Diagnostic Market: Disease Type Movement Analysis
• 6.3. Global Oncology Companion Diagnostic Market by Disease Type, Revenue
• 6.4. Breast Cancer
  • 6.4.1. Breast cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Non-small Cell Lung Cancer
  • 6.5.1. Non-small cell lung cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Colorectal Cancer
  • 6.6.1. Colorectal cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Leukemia
  • 6.7.1. Leukemia market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Melanoma
  • 6.8.1. Melanoma market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Prostate Cancer
  • 6.9.1. Prostate cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.10. Others
  • 6.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Oncology Companion Diagnostic Market: End-use Estimates & Trend Analysis

• 7.1. Global Oncology Companion Diagnostic Market: End-use Dashboard
• 7.2. Global Oncology Companion Diagnostic Market: End-use Movement Analysis
• 7.3. Global Oncology Companion Diagnostic Market by End-use, Revenue
• 7.4. Hospitals
  • 7.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Pathology/Diagnostic Laboratory
  • 7.5.1. Pathology/Diagnostic laboratory market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Academic Medical Center
  • 7.6.1. Academic medical center market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Oncology Companion Diagnostic Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2023
  • 9.3.4. Agilent Technologies, Inc.
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Illumina, Inc.
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. QIAGEN
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Thermo Fisher Scientific Inc.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Foundation Medicine, Inc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Myriad Genetics, Inc.
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. F. Hoffmann-La Roche Ltd.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. BioMerieux
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Abbott
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Leica Biosystems
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Guardant Health, Inc.
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Product benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. EntroGen, Inc.
    • 9.3.15.1. Company overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Product benchmarking
    • 9.3.15.4. Strategic initiatives

관련자료